SmithKline Beecham Corporation and Glaxo Group Limited (GSK) Deal History & Licensing Activity

About SmithKline Beecham Corporation and Glaxo Group Limited (GSK) Licensing & Deal Activity

SmithKline Beecham Corporation and Glaxo Group Limited (GSK) is a life sciences company that has been actively engaged in licensing transactions across the biopharma landscape. With 17 deals over the past three years, SmithKline Beecham Corporation and Glaxo Group Limited (GSK) ranks among the most acquisitive companies tracked by Ambrosia Ventures.

Key therapeutic areas of focus for SmithKline Beecham Corporation and Glaxo Group Limited (GSK) include Infectious Disease (12 deals and trials), Option Deals (7 deals and trials), Codev Deals (3 deals and trials), and Mega Deals (2 deals and trials). In terms of modality, SmithKline Beecham Corporation and Glaxo Group Limited (GSK) has shown particular interest in oligonucleotides, other, small molecules.

Ambrosia Ventures tracks deal terms, pipeline data, patent expirations, and competitive positioning for SmithKline Beecham Corporation and Glaxo Group Limited (GSK) and 850+ other biopharma companies. Use our deal calculator to benchmark your asset against SmithKline Beecham Corporation and Glaxo Group Limited (GSK)'s historical deal terms, or explore all company profiles to find the best partner match for your pipeline.